Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05118074 · ClinicalTrials.gov registry record
Nova Max Creatinine and eGFR Meter System
A clinical trial, sponsored by Nova Biomedical.
- Completed
- Registry status
- 360
- Enrollment target
NCT05118074 is a clinical trial that has completed, run by Nova Biomedical. The registered enrollment target is 360 participants.
The verdict
NCT05118074 has completed, sponsored by Nova Biomedical.
- COMPLETED
- Registry status
- 360 participants
- Enrollment target
Study Summary
To assess the performance of the Nova Max Creatinine and eGFR assay in the hands of CLIA-Waived Point-of-Care users in at least three (3) distinct Point-of-Care clinical settings on venous, and capillary blood and compare the performance characteristics to a traceable laboratory reference method (the Siemens EXL creatinine determination). To assess the Ease of Use of the Nova Max Creatinine and eGFR Meter System in the hands of the intended CLIA-Waived Point-of-Care users.
Interventions
- DIAGNOSTIC_TEST Creatinine, eGFR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2024-04-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05118074
The ClinicalTrials.gov registry entry for NCT05118074 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nova Biomedical, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Creatinine, eGFR is the first listed.
NCT05118074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05118074 about?
NCT05118074 is a clinical study titled "Nova Max Creatinine and eGFR Meter System". To assess the performance of the Nova Max Creatinine and eGFR assay in the hands of CLIA-Waived Point-of-Care users in at least three (3) distinct Point-of-Care clinical settings on venous, and capillary blood and compare the performance characteristics to a traceable laboratory reference method (th...
What is the current status of trial NCT05118074?
This trial is currently completed. The enrollment target is 360 participants. The study started on 2021-06-08. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT05118074?
The interventions under investigation include: Creatinine, eGFR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05118074?
This trial is sponsored by Nova Biomedical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.